ASTERIX: adaptive salvage treatment based on endotype-directed anti-virals and immunomodulation - an NHS framework to enable research and clinical trials
- Funded by CSO Scotland
- Total publications:0 publications
Grant number: COV/GLA/20/02
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$21,080Funder
CSO ScotlandPrincipal Investigator
Prof. Kevin BlythResearch Location
United KingdomLead Research Institution
University of GlasgowResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Clinical trials for disease management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Scotland is well-positioned to contribute to the urgent need for COVID-19 treatments. To do this we need to understand the disease and quickly bring new treatments to Scottish patients in trials. We will build the ASTERIX framework, which will be integrated into clinical systems so that frontline staff are not burdened, using repurposed NHS infrastructure and staff. ASTERIX will allow us to learn quickly, while under huge clinical pressures, and streamline patients into trials. Our learning will include how to treat COVID-19 and how to ensure that critical trial results are robust and relevant to Scottish patients.